Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis : Infliximab Versus Adalimumab
Purpose: Management of uveitis displays a particular challenge in childhood. This study aims to compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in pediatric noninfectious uveitis that were refractory to conventional immunosuppresives. Methods: This retrospective single-center study included 33 patients who were treated with anti-tumor necrosis factor (TNF) agents (16 with IFX and 17 with ADA). Patients had diverse etiologies, including juvenile idiopathic arthritis, idiopathic uveitis, and Behçet's disease. Demographic characteristics, systemic diagnosis, findings of the ophthalmological examination, control of ocular inflammation, response to treatment, and the rate of clinical remission were studied. Results: Fourteen (87.5%) patients receiving IFX and 10 (58.8%) patients receiving ADA achieved response to treatment during the follow-up (P = 0.118). The agents were discontinued with complete clinical remission in 6 (37.5%) patients receiving IFX and in 2 (11.8%) patients receiving ADA (P = 0.118). Baseline visual acuities and parameters of inflammation improved significantly in both groups after anti-TNF therapy. Conclusion: Both IFX and ADA are safe and effective for pediatric noninfectious uveitis.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
---|---|
Enthalten in: |
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics - 37(2021), 4 vom: 15. Mai, Seite 236-240 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ucan Gunduz, Gamze [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adalimumab |
---|
Anmerkungen: |
Date Completed 09.11.2021 Date Revised 09.11.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1089/jop.2020.0081 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM320737888 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM320737888 | ||
003 | DE-627 | ||
005 | 20231225174227.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1089/jop.2020.0081 |2 doi | |
028 | 5 | 2 | |a pubmed24n1069.xml |
035 | |a (DE-627)NLM320737888 | ||
035 | |a (NLM)33512278 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ucan Gunduz, Gamze |e verfasserin |4 aut | |
245 | 1 | 0 | |a Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis |b Infliximab Versus Adalimumab |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.11.2021 | ||
500 | |a Date Revised 09.11.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Purpose: Management of uveitis displays a particular challenge in childhood. This study aims to compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in pediatric noninfectious uveitis that were refractory to conventional immunosuppresives. Methods: This retrospective single-center study included 33 patients who were treated with anti-tumor necrosis factor (TNF) agents (16 with IFX and 17 with ADA). Patients had diverse etiologies, including juvenile idiopathic arthritis, idiopathic uveitis, and Behçet's disease. Demographic characteristics, systemic diagnosis, findings of the ophthalmological examination, control of ocular inflammation, response to treatment, and the rate of clinical remission were studied. Results: Fourteen (87.5%) patients receiving IFX and 10 (58.8%) patients receiving ADA achieved response to treatment during the follow-up (P = 0.118). The agents were discontinued with complete clinical remission in 6 (37.5%) patients receiving IFX and in 2 (11.8%) patients receiving ADA (P = 0.118). Baseline visual acuities and parameters of inflammation improved significantly in both groups after anti-TNF therapy. Conclusion: Both IFX and ADA are safe and effective for pediatric noninfectious uveitis | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a adalimumab | |
650 | 4 | |a infliximab | |
650 | 4 | |a noninfectious | |
650 | 4 | |a pediatric | |
650 | 4 | |a uveitis | |
650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
650 | 7 | |a Infliximab |2 NLM | |
650 | 7 | |a B72HH48FLU |2 NLM | |
650 | 7 | |a Adalimumab |2 NLM | |
650 | 7 | |a FYS6T7F842 |2 NLM | |
700 | 1 | |a Yalcinbayir, Ozgur |e verfasserin |4 aut | |
700 | 1 | |a Cekic, Sukru |e verfasserin |4 aut | |
700 | 1 | |a Yildiz, Meral |e verfasserin |4 aut | |
700 | 1 | |a Kilic, Sara S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics |d 1998 |g 37(2021), 4 vom: 15. Mai, Seite 236-240 |w (DE-627)NLM085101974 |x 1557-7732 |7 nnns |
773 | 1 | 8 | |g volume:37 |g year:2021 |g number:4 |g day:15 |g month:05 |g pages:236-240 |
856 | 4 | 0 | |u http://dx.doi.org/10.1089/jop.2020.0081 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 37 |j 2021 |e 4 |b 15 |c 05 |h 236-240 |